Cancer biology: Mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor

British Journal of Cancer

Volumn 95, Issue SUPPL. 1, 2006, Pages

  Richon, V M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Chromatin; Histone deacetylase; Vorinostat

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE DERIVATIVE; BAY 11 7085; BAY 117085; BEVACIZUMAB; BEXAROTENE; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ELLIPTICINE; ETOPOSIDE; FLAVOPIRIDOL; FLUOROURACIL; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IRINOTECAN; PERIFOSINE; PROTEIN BCL 6; PROTEIN INHIBITOR; PROTEIN P53; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR; TRASTUZUMAB; VORINOSTAT;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CARCINOMA; BREAST ADENOCARCINOMA; CANCER TISSUE; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL TRIAL; COLON CARCINOMA; CONFERENCE PAPER; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOMETRIUM CANCER; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; GLIOBLASTOMA; GLIOMA; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPHOMA; MANTLE CELL LYMPHOMA; MELANOMA; MESOTHELIOMA; MONONUCLEAR CELL; MYELOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; PROTEIN FUNCTION; STOMACH CANCER; THYROID CANCER; TREATMENT OUTCOME;

EID: 33845615494     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603463     Document Type: Conference Paper

References (43)

1. Almenara J, Rosato R, Grant S (2002) Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 16: 1331-1343
2. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis of antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280: 26729-26734
3. Bereshchenko OR, Gu W, Dalla-Favera R (2002) Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 32: 606-613
4. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60: 5165-5170
5. Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM (2005) Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62: 223-229
6. Cohen LA, Amin S, Marks PA, Rifkind RA, Desai D, Richon VM (1999) Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res 19: 4999-5005
7. Cohen LA, Marks PA, Rifkind RA, Amin S, Desai D, Pittman B, Richon VM (2002) Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res 22: 1497-1504
8. Desai D, Das A, Cohen L, el Bayoumy K, Amin S (2003) Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino) -1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. Anticancer Res 23: 499-503
9. Duvic M, Talpur R, Zhang C, Goy A, Richon VM, Frankel SR (2005) Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) unresponsive to conventional therapy. J Clin Oncol 23(suppl): 577s (abstract 6571)
10. Eyupoglu IY, Hahnen E, Buslei R, Siebzehnrubl FA, Savaskan NE, Luders M, Trankle C, Wick W, Weller M, Fahlbusch R, Blumcke I (2005) Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem 93: 992-999
11. Fenrick R, Hiebert SW (1998) Role of histone deacetylases in acute leukemia. J Cell Biochem Suppl 30-31: 194-202
12. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401: 188-193
13. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2: 151-163
14. Gregory PD, Wagner K, Horz W (2001) Histone acetylation and chromatin remodeling. Exp Cell Res 265: 195-202
15. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S, Pelicci PG (1998) Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391: 815-818
16. Grunstein M (1997) Histone acetylation in chromatin structure and transcription. Nature 389: 349-352
17. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA (2004) Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 101: 1241-1246
18. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN (2004) Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59: 177-189
19. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, Pandolfi PP (1998) Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 18: 126-135
20. He LZ, Tolentino T, Grayson P, Zhong S, Warrell Jr RP, Rifkind RA, Marks PA, Richon VM, Pandolfi PP (2001) Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108: 1321-1330
21. Johnstone RW, Licht JD (2003) Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4: 13-18
22. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, Macgregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic Acid, in patients with advanced cancer. J Clin Oncol 23: 3923-3931
23. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9: 3578-3588
24. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291-7300
25. Lemercier C, Brocard MP, Puvion-Dutilleul F, Kao HY, Albagli O, Khochbin S (2002) Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J Biol Chem 277: 22045-22052
26. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN (2004) Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 92: 223-237
27. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202
28. Marks PA, Dokmanovic M (2005) Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14: 1497-1511
29. Marks PA, Richon VM, Miller T, Kelly WK (2004) Histone deacetylase inhibitors. Adv Cancer Res 91: 137-168
30. Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K (2003) Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101: 3236-3239
31. Ocker M, Alajati A, Ganslmayer M, Zopf S, Luders M, Neureiter D, Hahn EG, Schuppan D, Herold C (2005) The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol 131: 385-394
32. Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, Spiegel S, Grant S (2005) Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 65: 2422-2432
33. Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, Grant S (2003) Coadministration of the heat shock protein 90 antagonist 17-allylamino-17- demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 63: 8420-8427
34. Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014-10019
35. Rundall BK, Denlinger CE, Jones DR (2004) Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death. Surgery 136: 416-425
36. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP (2005) Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 33: 53-61
37. Sandor V, Robbins AR, Robey R, Myers T, Sausville E, Bates SE, Sackett DL (2000) FR901228 causes mitotic arrest but does not alter microtubule polymerization. Anticancer Drugs 11: 445-454
38. Secrist JP, Zhou X, Richon VM (2003) HDAC inhibitors for the treatment of cancer. Curr Opin Investig Drugs 4: 1422-1427
39. Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY, Lee SH, Park WS, Yoo NJ, Lee JY, Nam SW (2005) Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 113: 264-268
40. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, Marks PA (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 673-678
41. Verdin E, Dequiedt F, Kasler HG (2003) Class II histone deacetylases: versatile regulators. Trends Genet 19: 286-293
42. Warrener R, Beamish H, Burgess A, Waterhouse NJ, Giles N, Fairlie D, Gabrielli B (2003) Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J 17: 1550-1552
43. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5: 455-463